Peter Kolchinsky portfolio, Q3 2025
RA Capital Management · 13F for the quarter ending Sep 30, 2025
For Q3 2025, RA Capital Management reported $8.1B across 67 US-listed positions, led by ASND (25.2%), RYTM (7.1%) and PCVX (5.3%). Compared with its filing for Q2 2025, Peter Kolchinsky opened 15 new positions, added to 7, reduced 1 and sold out of 11; 43 positions did not change.
The largest purchase was a new position in Nuvalent Inc ($107.8M); the largest sale, the sale of the whole position in DYN ($92.5M).
Key facts
- 13F portfolio value
- $8.1BQ3 2025
- Positions
- 67
- Largest holding
- ASND 25.2%
- New positions
- 15
- Sold out
- 11
- Filed
- Nov 14, 2025
Holdings as of (Q3 2025), filed with the SEC on . Changes are measured against the filing for Jun 30, 2025. Every tracked investor's Q3 2025 13F.
Bought and sold in Q3 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
Nuvalent Incno ticker on file | ▲ New | +1.25M | $107.8M | 1.33% |
| Dyne Therapeutics IncDYN | ▼ Sold out | −9.71M | $92.5M | 1.14% |
| Belite Bio IncBLTE | ▲ New | +875K | $64.8M | 0.80% |
Avidity Biosciences Incno ticker on file | ▲ Added 19% | +1.38M | $59.9M | 0.74% |
| RxSight IncRXST | ▼ Sold out | −3.7M | $48.1M | 0.59% |
| Mineralys Therapeutics IncMLYS | ▲ Added 19% | +1.18M | $44.6M | 0.55% |
| Pepgen IncPEPG | ▲ Added 88% | +9.38M | $43.3M | 0.53% |
Tourmaline Bio Incno ticker on file | ▼ Sold out | −2.54M | $40.6M | 0.50% |
| LB Pharmaceuticals IncLBRX | ▲ New | +1.78M | $28.1M | 0.35% |
| Assembly Biosciences IncASMB | ▲ New | +1.02M | $26.1M | 0.32% |
| Contineum Therapeutics IncCTNM | ▲ New | +2.12M | $24.9M | 0.31% |
| Invivyd IncIVVD | ▲ New | +17.12M | $18.8M | 0.23% |
| Enliven Therapeutics IncELVN | ▼ Sold out | −848.99K | $17M | 0.21% |
| Prime Medicine IncPRME | ▲ New | +3M | $16.6M | 0.20% |
| Hinge Health IncHNGE | ▼ Sold out | −300K | $15.5M | 0.19% |
| Rhythm Pharmaceuticals IncRYTM | ▲ Added 2.2% | +120K | $12.1M | 0.15% |
| Uniqure NVQURE | ▲ New | +200K | $11.7M | 0.14% |
| Sab Biotherapeutics IncSABS | ▲ New | +4.4M | $8.8M | 0.11% |
| Edgewise Therapeutics IncEWTX | ▲ Added 5.3% | +525.8K | $8.5M | 0.11% |
| Inspire Med Systems IncINSP | ▲ New | +114.9K | $8.5M | 0.11% |
| Omada Health IncOMDA | ▼ Sold out | −400K | $7.3M | 0.09% |
| Beta Bionics IncBBNX | ▼ Sold out | −500K | $7.3M | 0.09% |
| 10X Genomics IncTXG | ▼ Sold out | −475.34K | $5.5M | 0.07% |
| Evolent Health IncEVH | ▲ New | +579.05K | $4.9M | 0.06% |
| Glaukos CorpGKOS | ▲ New | +54.18K | $4.4M | 0.05% |
| MBX Biosciences IncMBX | ▼ Sold out | −377.84K | $4.3M | 0.05% |
| Design Therapeutics IncDSGN | ▲ New | +475.7K | $3.6M | 0.04% |
| Avalo Therapeutics IncAVTX | ▼ Reduced 29% | −270.01K | $3.4M | 0.04% |
| Protara Therapeutics IncTARA | ▼ Sold out | −1.04M | $3.1M | 0.04% |
Exact Sciences Corpno ticker on file | ▲ New | +54.94K | $3M | 0.04% |
| Progyny IncPGNY | ▲ New | +96.63K | $2.1M | 0.03% |
| Acadia Healthcare CompanyACHC | ▼ Sold out | −89.26K | $2M | 0.02% |
| Scholar Rock Holding CorpSRRK | ▲ Added 2.7% | +30.34K | $1.1M | 0.01% |
| Solid Biosciences IncSLDB | ▲ Added 0.00% | +100 | $617 | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q2 2025 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 25.2% | $2B | 10.28M | $198.81 | 6+ qtrs | No change |
| 2 | Rhythm Pharmaceuticals IncRYTM | Health Care | 7.07% | $573.8M | 5.68M | $100.99 | 6+ qtrs | ▲ Added 2.2% |
| 3 | Vaxcyte IncPCVX | Health Care | 5.31% | $431M | 11.97M | $36.02 | 6+ qtrs | No change |
| 4 | Avidity Biosciences Incno ticker on file · SH | — | 4.64% | $376.5M | 8.64M | $43.57 | 6+ qtrs | ▲ Added 19% |
| 5 | Cidara Therapeutics Incno ticker on file · SH | — | 3.97% | $322.3M | 3.37M | $95.76 | 5 qtrs | No change |
| 6 | Sionna Therapeutics IncSION | — | 3.79% | $307.2M | 10.45M | $29.41 | 3 qtrs | No change |
| 7 | 89BIO Incno ticker on file · SH | — | 3.60% | $292.4M | 19.89M | $14.70 | 6+ qtrs | No change |
| 8 | Newamsterdam Pharma CompanyNAMS | — | 3.55% | $288.4M | 10.14M | $28.44 | 6+ qtrs | No change |
| 9 | Mineralys Therapeutics IncMLYS | — | 3.42% | $277.7M | 7.32M | $37.92 | 6+ qtrs | ▲ Added 19% |
| 10 | Janux Therapeutics IncJANX | — | 3.37% | $273.5M | 11.19M | $24.44 | 6+ qtrs | No change |
| 11 | Arcellx Incno ticker on file · SH | — | 3.07% | $249.3M | 3.04M | $82.10 | 6+ qtrs | No change |
| 12 | Lenz Therapeutics IncLENZ | — | 2.40% | $194.6M | 4.18M | $46.58 | 6+ qtrs | No change |
| 13 | Tyra Biosciences IncTYRA | — | 2.10% | $170.7M | 12.2M | $13.99 | 6+ qtrs | No change |
| 14 | Edgewise Therapeutics IncEWTX | Health Care | 2.08% | $169.1M | 10.43M | $16.22 | 6+ qtrs | ▲ Added 5.3% |
| 15 | Wave Life Sciences LtdWVE | — | 1.64% | $133.2M | 18.2M | $7.32 | 6+ qtrs | No change |
| 16 | Septerna IncSEPN | — | 1.62% | $131.6M | 7M | $18.81 | 4 qtrs | No change |
| 17 | Dianthus Therapeutics IncDNTH | Health Care | 1.39% | $112.8M | 2.87M | $39.35 | 6+ qtrs | No change |
| 18 | Bicara Therapeutics IncBCAX | — | 1.35% | $109.8M | 6.96M | $15.79 | 5 qtrs | No change |
| 19 | GH Research PLCGHRS | — | 1.35% | $109.8M | 7.68M | $14.30 | 6+ qtrs | No change |
| 20 | Ars Pharmaceuticals IncSPRY | — | 1.35% | $109.2M | 10.86M | $10.05 | 6+ qtrs | No change |
| 21 | Nuvalent Incno ticker on file | — | 1.33% | $107.8M | 1.25M | $86.48 | 1 qtr | New |
| 22 | Disc Medicine IncIRON | — | 1.28% | $104.2M | 1.58M | $66.08 | 3 qtrs | No change |
| 23 | Vor Biopharma IncVOR | — | 1.19% | $96.6M | 1.98M | $48.72 | 6+ qtrs | — |
| 24 | Fulcrum Therapeutics IncFULC | — | 1.16% | $94.1M | 10.23M | $9.20 | 6+ qtrs | No change |
| 25 | Pepgen IncPEPG | — | 1.14% | $92.7M | 20.06M | $4.62 | 6+ qtrs | ▲ Added 88% |
| 26 | Geron CorpGERN | — | 1.02% | $82.7M | 60.38M | $1.37 | 6+ qtrs | No change |
| 27 | Taysha Gene Therapies IncTSHA | — | 0.95% | $77M | 23.56M | $3.27 | 6+ qtrs | No change |
| 28 | Belite Bio IncBLTE · SH | Health Care | 0.80% | $64.8M | 875K | $74.00 | 1 qtr | New |
| 29 | Climb Bio IncCLYM | — | 0.78% | $63.2M | 31.42M | $2.01 | 6+ qtrs | No change |
| 30 | Scholar Rock Holding CorpSRRK · SH | Health Care | 0.54% | $43.5M | 1.17M | $37.24 | 4 qtrs | ▲ Added 2.7% |
| 31 | Structure Therapeutics IncGPCR · SH | — | 0.52% | $42.5M | 1.52M | $28.00 | 6+ qtrs | No change |
| 32 | Monopar Therapeutics IncMNPR | — | 0.51% | $41.8M | 511.21K | $81.67 | 4 qtrs | No change |
| 33 | 4D Molecular TherapeuticsFDMT | — | 0.49% | $39.7M | 4.56M | $8.69 | 6+ qtrs | No change |
| 34 | Solid Biosciences IncSLDB | — | 0.44% | $35.9M | 5.81M | $6.17 | 6+ qtrs | ▲ Added 0.00% |
| 35 | Metsera Incno ticker on file · SH | — | 0.44% | $35.4M | 675.53K | $52.33 | 3 qtrs | No change |
| 36 | Artiva Biotherapeutics IncARTV | — | 0.35% | $28.3M | 9.85M | $2.87 | 5 qtrs | No change |
| 37 | LB Pharmaceuticals IncLBRX | — | 0.35% | $28.1M | 1.78M | $15.79 | 1 qtr | New |
| 38 | Travere Therapeutics IncTVTX | Health Care | 0.34% | $27.5M | 1.15M | $23.90 | 4 qtrs | No change |
| 39 | Assembly Biosciences IncASMB | — | 0.32% | $26.1M | 1.02M | $25.60 | 1 qtr | New |
| 40 | Acumen Pharmaceuticals IncABOS | — | 0.32% | $25.5M | 14.93M | $1.71 | 6+ qtrs | No change |
| 41 | Contineum Therapeutics IncCTNM | — | 0.31% | $24.9M | 2.12M | $11.75 | 1 qtr | New |
| 42 | Nkarta IncNKTX | — | 0.28% | $22.4M | 10.81M | $2.07 | 6+ qtrs | No change |
| 43 | Larimar Therapeutics IncLRMR · SH | — | 0.24% | $19.5M | 6.05M | $3.23 | 6+ qtrs | No change |
| 44 | Invivyd IncIVVD · SH | — | 0.23% | $18.8M | 17.12M | $1.10 | 1 qtr | New |
| 45 | Tango Therapeutics IncTNGX · SH | — | 0.21% | $16.8M | 2M | $8.40 | 2 qtrs | No change |
| 46 | Prime Medicine IncPRME · SH | — | 0.21% | $16.6M | 3M | $5.54 | 1 qtr | New |
| 47 | Arcus Biosciences IncRCUS · SH | — | 0.19% | $15.5M | 1.14M | $13.60 | 3 qtrs | No change |
| 48 | Acrivon Therapeutics IncACRV | — | 0.19% | $15.1M | 8.34M | $1.81 | 6+ qtrs | No change |
| 49 | Werewolf Therapeutics IncHOWL | — | 0.16% | $13.2M | 6.68M | $1.97 | 6+ qtrs | No change |
| 50 | Uniqure NVQURE · SH | — | 0.14% | $11.7M | 200K | $58.37 | 1 qtr | New |
| 51 | Eledon Pharmaceuticals IncELDN · SH | — | 0.11% | $9.2M | 3.57M | $2.59 | 4 qtrs | No change |
| 52 | Jade Biosciences IncJBIO | — | 0.11% | $9.2M | 1.06M | $8.63 | 2 qtrs | No change |
| 53 | Sab Biotherapeutics IncSABS | — | 0.11% | $8.8M | 4.4M | $2.01 | 1 qtr | New |
| 54 | Inspire Med Systems IncINSP | — | 0.11% | $8.5M | 114.9K | $74.20 | 1 qtr | New |
| 55 | CytomX Therapeutics IncCTMX · SH | — | 0.11% | $8.5M | 2.66M | $3.19 | 3 qtrs | No change |
| 56 | Avalo Therapeutics IncAVTX | — | 0.10% | $8.4M | 662.97K | $12.71 | 5 qtrs | ▼ Reduced 29% |
| 57 | Perceptive Cap Solutionsno ticker on file | — | 0.10% | $8M | 750K | $10.60 | 6+ qtrs | No change |
| 58 | Surrozen IncSRZN · SH | — | 0.10% | $7.8M | 602.63K | $12.88 | 6+ qtrs | No change |
| 59 | GeneDx Holdings CorpWGS | — | 0.08% | $6.3M | 58.04K | $107.74 | 2 qtrs | No change |
| 60 | Adicet Bio IncACET · SH | — | 0.08% | $6.1M | 7.54M | $0.8102 | 6+ qtrs | No change |
| 61 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.07% | $5.7M | 333.33K | $17.11 | 6+ qtrs | No change |
| 62 | Evolent Health IncEVH · SH | — | 0.06% | $4.9M | 579.05K | $8.46 | 1 qtr | New |
| 63 | Glaukos CorpGKOS · SH | Health Care | 0.05% | $4.4M | 54.18K | $81.55 | 1 qtr | New |
| 64 | Design Therapeutics IncDSGN | — | 0.04% | $3.6M | 475.7K | $7.53 | 1 qtr | New |
| 65 | Exact Sciences Corpno ticker on file · SH | — | 0.04% | $3M | 54.94K | $54.71 | 1 qtr | New |
| 66 | Inflarx NVIFRX · SH | — | 0.03% | $2.6M | 1.97M | $1.34 | 2 qtrs | No change |
| 67 | Progyny IncPGNY · SH | — | 0.03% | $2.1M | 96.63K | $21.52 | 1 qtr | New |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 42.8% | $3.5B | 9 |
| No sector on file | 57.2% | $4.6B | 58 |
Questions and answers
What did Peter Kolchinsky own in Q3 2025?
RA Capital Management's 13F for Q3 2025 lists 67 positions worth $8.1B. The largest: ASND (25.2%), RYTM (7.1%), PCVX (5.3%), Avidity Biosciences Inc (4.6%), Cidara Therapeutics Inc (4.0%).
What did Peter Kolchinsky buy in Q3 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: Nuvalent Inc (new, $107.8M), BLTE (new, $64.8M), Avidity Biosciences Inc (added, $59.9M), MLYS (added, $44.6M), PEPG (added, $43.3M), LBRX (new, $28.1M).
What did Peter Kolchinsky sell in Q3 2025?
The largest sales: DYN (sold out, $92.5M), RXST (sold out, $48.1M), Tourmaline Bio Inc (sold out, $40.6M), ELVN (sold out, $17M), HNGE (sold out, $15.5M), OMDA (sold out, $7.3M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Sep 30, 2025 on Nov 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q3 2025: RA Capital Management 13F holdings”, data as of 14 November 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q3
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Sep 30, 2025.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Sep 30, 2025, filed Nov 14, 2025. Changes compare share counts with the filing for Jun 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $8.1B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 6 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.